- Home
- LBTYK vs TLX Comparison
LBTYK vs TLX Comparison
Compare LBTYK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYK | TLX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Bermuda | Australia |
| Employees | 6636 | 1184 |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LBTYK | TLX |
|---|---|---|
| Price | $11.23 | $10.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $21.13 |
| AVG Volume (30 Days) | ★ 1.6M | 193.8K |
| Earning Date | 02-18-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.21 | $6.28 |
| 52 Week High | $13.12 | $18.99 |
Technical Indicators
Market Signals| Indicator | LBTYK | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 60.20 |
| Support Level | $10.59 | $9.46 |
| Resistance Level | $11.51 | $11.28 |
| Average True Range (ATR) | 0.33 | 0.29 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 6.40 | 43.20 |
Price Performance
Historical ComparisonAbout LBTYK Liberty Global Ltd. Class C
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.